Lodestar Investment Counsel LLC IL grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 99,561 shares of the medical research company’s stock after purchasing an additional 1,676 shares during the quarter. Amgen makes up about 2.2% of Lodestar Investment Counsel LLC IL’s investment portfolio, making the stock its 12th largest position. Lodestar Investment Counsel LLC IL’s holdings in Amgen were worth $17,147,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Camelot Portfolios LLC bought a new position in Amgen during the 1st quarter worth approximately $1,429,000. Cadence Bank NA grew its position in Amgen by 6.2% during the 1st quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after acquiring an additional 197 shares during the last quarter. Osborne Partners Capital Management LLC grew its position in Amgen by 0.5% during the 2nd quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock worth $2,932,000 after acquiring an additional 91 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its position in Amgen by 70.6% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock worth $6,377,000 after acquiring an additional 16,080 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. grew its position in Amgen by 21.5% during the 1st quarter. Adams Diversified Equity Fund Inc. now owns 127,000 shares of the medical research company’s stock worth $20,837,000 after acquiring an additional 22,500 shares during the last quarter. Hedge funds and other institutional investors own 78.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/06/lodestar-investment-counsel-llc-il-purchases-1676-shares-of-amgen-inc-amgn.html.

Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.55% during mid-day trading on Wednesday, hitting $177.72. The company had a trading volume of 814,381 shares. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The company has a 50-day moving average price of $173.66 and a 200-day moving average price of $168.55. The company has a market capitalization of $129.68 billion, a price-to-earnings ratio of 16.19 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $2.84 EPS. On average, equities analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a $1.15 dividend. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.60%. Amgen’s dividend payout ratio (DPR) is 41.93%.

Several equities analysts recently issued reports on AMGN shares. BMO Capital Markets restated a “buy” rating and set a $198.00 price target (down from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a research report on Monday, June 5th. ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Mizuho restated a “buy” rating and set a $195.00 price target on shares of Amgen in a research report on Sunday, July 9th. Finally, Jefferies Group LLC restated a “buy” rating and set a $195.00 price target on shares of Amgen in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $186.04.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.